Clinical Trials
4
Active:0
Completed:2
Trial Phases
3 Phases
Phase 1:2
Phase 2:1
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (50.0%)Phase 2
1 (25.0%)Phase 3
1 (25.0%)Clinical Study to Investigate the Safety and Tolerance of Therapeutic BCG in Postoperative Adjuvant Therapy in Subjects With Moderate to High-risk Non-muscular Invasive Bladder Cancer (NMIBC)
Phase 1
Completed
- Conditions
- Non-muscular Invasive Bladder Cancer
- Interventions
- First Posted Date
- 2024-04-05
- Last Posted Date
- 2024-04-05
- Lead Sponsor
- Chengdu CoenBiotech Co., Ltd
- Target Recruit Count
- 10
- Registration Number
- NCT06350838
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
Clinical Trial to Explore the Skin Test Dosage of EEC in People Aged 18 to 65 Years Old and the Safety and Preliminary Efficacy in People Aged 3 to 75 Years Old.
Phase 2
Recruiting
- Conditions
- Tuberculosis
- First Posted Date
- 2024-03-12
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Chengdu CoenBiotech Co., Ltd
- Target Recruit Count
- 420
- Registration Number
- NCT06305104
- Locations
- 🇨🇳
Beijing Chest Hospital, Beijing, Beijing, China
🇨🇳Wuhan Institute for Tuberculosis Control, Wuhan, Hubei, China
🇨🇳Changde First People's Hospital, Changde, Hunan, China
Clinical Trial for Evaluating the Efficacy and Safety of BCG for Therapeutic Use in the Prevention of Postoperative Recurrence of Medium/High-risk Non-muscle Invasive Bladder Cancer (NMIBC)
Phase 3
Recruiting
- Conditions
- Non-Muscle Invasive Bladder Cancer
- Interventions
- First Posted Date
- 2024-02-05
- Last Posted Date
- 2024-02-05
- Lead Sponsor
- Chengdu CoenBiotech Co., Ltd
- Target Recruit Count
- 412
- Registration Number
- NCT06241755
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital,Sun Yat-sen University, Guangzhou, Guangdong, China
Phase I Clinical Trial to Evaluate the Safety of Recombinant Mycobacterium Tuberculosis Fusion Protein (EEC) in Healthy Adults Aged 18-65 and Patients With Pulmonary Tuberculosis
Phase 1
Completed
- Conditions
- Tuberculosis
- First Posted Date
- 2024-01-25
- Last Posted Date
- 2024-01-25
- Lead Sponsor
- Chengdu CoenBiotech Co., Ltd
- Target Recruit Count
- 60
- Registration Number
- NCT06224608
- Locations
- 🇨🇳
Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳Beijing Chest Hospital, Capital Medical University, Beijing, Beijing, China
News
No news found